NDA 20-152/S-014/S-025

Bristol-Myers Squibb Company
Attention: Ronald Marcus, M.D.
Group Director, Regulatory Science
Five Research Parkway
Wallingford, CT 06492

JAN 23 2001

Dear Dr. Marcus:

Please refer to your supplemental new drug applications dated July 6, 1998 (S-014), and November 21, 2000 (S-025), submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for Serzone (nefazodone hydrochloride) 50 mg, 100 mg, 150 mg, 200 mg, and 250 mg Tablets.

Reference is also made to an Agency approvable letter dated June 1, 2000, for S-014.

Supplemental application S-025, submitted under "Changes Being Effected", provides for the following labeling revisions:

1. The addition of a new subsection entitled **PRECAUTIONS-Drug Interactions-CNS Active Drugs-Buspirone** which was previously submitted under S-014 as a "Changes Being Effected" supplement. However, the last 4 sentences under this subsection have been deleted.
2. The revision of the subsection entitled **$IIIA_4$ Isozyme** in the **PRECAUTIONS-Drug Interactions** section.
3. The addition of a new subsection entitled **Visual Disturbances** under both the **PRECAUTIONS-Information for Patients** and the **ADVERSE REACTIONS-Incidence in Controlled Trials** sections.
4. The reformatting of the **ADVERSE REACTIONS-Postintroduction Clinical Experience** section and the addition of the following terms to this section: anaphylactic reactions, angioedema, galactorrhea, gynecomastia (male), prolactin increased, serotonin syndrome, and Steven's Johnson syndrome

We have completed the review of this supplemental application, S-025, and have concluded that adequate information has been presented to demonstrate that the drug product is safe and effective for use as recommended in the submitted final printed labeling (package insert submitted November 21, 2000/Label Code1092982A7), which incorporates all of the revisions listed. Accordingly, this supplemental application is approved effective on the date of this letter.

Labeling changes of the kind which you have proposed under the above supplemental application are permitted by section 314.70(c) of the regulations to be instituted prior to approval of the supplement. It is understood that the changes, described in the above NDA supplement, have been made.

We additionally note that the labeling changes submitted in S-025 supercede the labeling revisions proposed in S-014, in which the Agency issued an approvable letter dated June 1, 2000, and you are requesting that S-014 be withdrawn.

Therefore, in accordance with 21 CFR 314.65, this supplemental application is withdrawn as of the date of our receipt of your notification, November 22, 2000. This withdrawal does not prejudice any future filing of the applications. You may request that the information contained in these withdrawn supplemental applications be considered in conjunction with any future submission.

If a letter communicating important information about this drug product (i.e., a "Dear Health Care Practitioner" letter) is issued to physicians and others responsible for patient care, we request that you submit a copy of the letter to this NDA and a copy to the following address:

MEDWATCH, HF-2
FDA
5600 Fishers Lane
Rockville, MD 20857

We remind you that you must comply with the requirements for an approved NDA set forth under 21 CFR 314.80 and 314.81.

If you have any questions, call Mr. Paul David, R.Ph., Regulatory Project Manager, at (301) 594-5530.

Sincerely,

Russell Katz, M.D.
Director
Division of Neuropharmacological Drug Products
Office of Drug Evaluation I
Center for Drug Evaluation and Research